Treatment with the combination of Dabrafenib and Trametinib (Dab/Trame; a standard treatment in BRAF-mutant melanomas) had no effect on the migration of ShShcD cells compared to the control cells, showing that the drug response to the inhibition of the BRAF/MEK pathway is not influenced by the depletion of ShcD. This evidence concerns the gene SHC4 and melanoma.